|
The relationship of TP53 R72P polymorphism to disease outcome and TP53 mutation in myelodysplastic syndromes
|
Mar 2015
|
Blood Cancer J
|
myelodysplastic syndromes (MDS)
|
|
Paroxysmal nocturnal hemoglobinuria and concurrent JAK2(V617F) mutation
|
Mar 2012
|
Blood Cancer J
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Poly (ADP-ribose) polymerase 1 mRNA levels strongly correlate with the prognosis of myelodysplastic syndromes.
|
Feb 2017
|
Blood Cancer J
|
myelodysplastic syndromes (MDS)
|
|
A retrospective study of paroxysmal nocturnal hemoglobinuria in pediatric and adolescent patients
|
Mar 2017
|
Blood Cells Mol Dis
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Diagnosis and management of acquired aplastic anemia in childhood. Guidelines from the Marrow Failure Study Group of the Pediatric Haemato-Oncology Italian Association (AIEOP)
|
Mar 2015
|
Blood Cells Mol Dis
|
aplastic anemia
|
|
Genetics factors associated with myelodysplastic syndromes
|
Apr 2015
|
Blood Cells Mol Dis
|
myelodysplastic syndromes (MDS)
|
|
Frequency and perturbations of various peripheral blood cell populations before and after eculizumab treatment in paroxysmal nocturnal hemoglobinuria
|
Mar 2021
|
Blood cells, molecules and diseases
|
paroxysmal nocturnal hemoglobinuria (PNH)
|
|
Pathogenesis of MDS: An Overview of molecular and non-molecular aspects of the disease
|
Dec 2014
|
Blood Res
|
myelodysplastic syndromes (MDS)
|
|
Pathogenesis of myelodysplastic syndromes: an overview of molecular and non-molecular aspects of the disease
|
Dec 2014
|
Blood Res
|
myelodysplastic syndromes (MDS)
|
|
Use of azacitidine for myelodysplastic syndromes: controversial issues and practical recommendations.
|
Jun 2013
|
Blood Res
|
myelodysplastic syndromes (MDS)
|
